HBOT and Gut Health: Exploring the Connection
By OxyPlus — Newcastle's Specialist Hyperbaric Oxygen Therapy Clinic oxyplus.co.uk | Updated August 2026 | 8 min read
The gut is not just a digestive organ. It is one of the most metabolically complex systems in the body. Home to trillions of microorganisms, a central pillar of immune function, a producer of neurotransmitters that influence mood and cognition, and a barrier whose integrity determines what enters the bloodstream and what does not.
When the gut is not working well, the effects are rarely confined to digestion. Chronic gut inflammation has been linked to fatigue, skin conditions, joint pain, brain fog, mood disorders, and systemic inflammatory conditions. The gut-brain axis (the bidirectional communication network between the gastrointestinal tract and the central nervous system) means that what happens in the gut does not stay in the gut.
Hyperbaric oxygen therapy has attracted serious clinical attention as an approach for inflammatory bowel disease (IBD), one of the most active areas of HBOT research. More broadly, the mechanisms through which HBOT influences inflammation, tissue oxygenation, and immune modulation are directly relevant to gut health in ways that extend beyond IBD.
At OxyPlus, our HBOT clinic in Newcastle, this is a topic our clients ask about with increasing frequency. This post explains what the gut needs to function well, what goes wrong in common gut conditions, and what the current evidence says about HBOT's role.
Why the Gut Needs Oxygen - More Than You Might Think
The intestinal lining (the epithelium) is exposed to a uniquely challenging oxygen environment. Normally, the GI tract does not have high levels of oxygen tension at the surface of the lining of the interior, and human bodies are adept at dealing with fluctuations in oxygen.</cite>
This sounds paradoxical, the gut functioning normally in a relatively low-oxygen environment, but it reflects the gut's adaptation to a microenvironment shaped by the presence of billions of anaerobic bacteria in the lumen. The epithelial cells do their metabolic work with a tightly regulated oxygen supply.
The problem arises when this balance is disrupted. When there are breaks in the lining, like what happens in IBD, and there is exposure to bacteria, immune cells infiltrate and consume whatever oxygen is there very rapidly.
This creates a cycle of tissue hypoxia at the sites of inflammation, the same kind of hypoxia that impairs healing in wounds elsewhere in the body. Hypoxic gut tissue cannot repair itself, cannot maintain its epithelial barrier, and cannot resolve the inflammation driving the damage. The result is the chronic, relapsing pattern of inflammation that defines conditions like Crohn's disease and ulcerative colitis.
HBOT may exert its therapeutic effects by decreasing oxidative stress, inhibiting mucosal inflammation, promoting ulcer healing, influencing gut microbes, and reducing the incidence of IBD complications.
The Evidence: HBOT in Inflammatory Bowel Disease
Crohn's Disease - The 2025 Clinical Study
The most specific recent evidence comes from a 2025 study published in the Journal of Translational Medicine examining HBOT in Crohn's disease patients. The study divided CD patients into an HBOT group and a control group and assessed both clinical markers and gut microbiota composition through 16S rRNA gene sequencing.
HBOT significantly reduced the level of C-reactive protein (CRP) (80.79 ± 42.05 mg/L vs. 33.32 ± 18.31 mg/L, P = 0.004) and the Crohn's Disease Activity Index (CDAI).
A reduction in CRP from approximately 81 to 33 mg/L is a substantial and clinically meaningful decrease in systemic inflammation - the kind of reduction that translates into meaningful improvements in symptoms and quality of life.
Critically, the study also found that HBOT modulated the composition of the gut microbiota. This is a significant finding: it suggests HBOT is not just addressing the inflammatory symptoms of Crohn's disease but influencing the microbial environment that drives and perpetuates it.
HBOT is a safe option for CD and exhibits a promising auxiliary effect to ustekinumab, one of the leading biologic medications used for Crohn's disease.
Ulcerative Colitis - Active Multicentre Trials
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in the United States is currently funding a multicentre consortium trial (the HBOT-UC Consortium) examining HBOT specifically for hospitalised patients with severe ulcerative colitis flares. The University of Miami Miller School of Medicine is one of 15 sites conducting clinical trials on the impact of hyperbaric oxygen therapy on ulcerative colitis.
The fact that this trial is running across 15 sites, funded by the NIDDK, reflects the seriousness with which the gastroenterological research community is now taking HBOT as an IBD intervention. As the principal investigator, Dr Oriana Damas, says: "Therapies for ulcerative colitis exist, but it's difficult to predict their effectiveness."
A 2024 review published in Gastroenterology & Hepatology summarised the current position: if positive, this trial should cement the use of hyperbaric oxygen therapy in that population and allow for its expansion into the outpatient setting, as well as the studying of it in other scenarios.
Case Evidence: Long-Standing UC in Remission
Beyond the clinical trials, the published case literature is instructive. After undergoing 60 HBOT sessions, one patient attained a state of full remission. A 65-year-old male patient with a 17-year history of ulcerative colitis achieved remission following HBOT.
While individual case reports are not the basis for clinical recommendations, cases of long-standing, treatment-resistant UC reaching remission following HBOT (when conventional therapy had not achieved this) reflect outcomes that merit systematic investigation.
The 2024 Precision Clinical Medicine Review
A comprehensive review published in the Oxford journal Precision Clinical Medicine in 2024 summarised the accumulating IBD evidence: related research has shown that HBOT may exert its therapeutic effects by decreasing oxidative stress, inhibiting mucosal inflammation, promoting ulcer healing, influencing gut microbes, and reducing the incidence of IBD complications.
How HBOT Affects Gut Health: The Mechanisms
1. Reversing Mucosal Hypoxia
The most direct mechanism is the correction of tissue hypoxia in inflamed gut tissue. When immune cells infiltrate an area of intestinal inflammation and consume available oxygen, the resulting hypoxic environment impairs epithelial repair and sustains the inflammatory cycle. HBOT increases the dissolved oxygen available throughout the body - including in the gut wall and mucosa - providing the substrate that healing tissue needs to restore its epithelial barrier.
2. Modulating the Gut Microbiome
The 2025 Crohn's study is particularly important for this mechanism. Through 16S rRNA gene sequencing, direct microbiota composition analysis, the researchers found that HBOT changed the relative abundance of key bacterial populations in the gut.
This is mechanistically coherent. Dysbiosis of the gut microbiota is pivotal in Crohn's disease and modulated by host physiological conditions. Many of the bacteria that proliferate in gut dysbiosis are anaerobic or facultatively anaerobic, meaning they thrive in the low-oxygen gut environment. HBOT's oxygenation of gut tissue creates a less hospitable environment for harmful anaerobes while supporting the aerotolerant bacteria associated with gut health.
3. Reducing Intestinal Inflammation
HBOT's well-established anti-inflammatory effects, reductions in TNF-α, IL-1β, IL-6, and NF-κB pathway activity, are directly relevant to gut inflammation. TNF-α in particular is one of the primary drivers of IBD pathology; it is the target of some of the most effective IBD biologics (infliximab, adalimumab). HBOT reduces TNF-α through a different mechanism, not by blocking it pharmacologically but by reducing the upstream oxygen-deprivation signalling that drives its overproduction. For the detailed inflammation mechanisms, see our post on How HBOT May Reduce Inflammation.
4. Supporting Intestinal Barrier Integrity
The intestinal epithelial barrier (the single layer of cells that separates the gut lumen from the bloodstream) depends on intact tight junction proteins including occludin, claudin-1, and zonulin to maintain its selective permeability. When these tight junctions are disrupted, the result is increased intestinal permeability (sometimes called "leaky gut") in which bacterial products including lipopolysaccharides (LPS) pass into the circulation and trigger systemic inflammation.
HBOT's oxygenation of the epithelial layer, combined with its anti-inflammatory effects, supports the restoration of tight junction integrity. Healing a chronically inflamed, hypoxic epithelium (rather than just suppressing the inflammation pharmacologically) addresses the structural basis of barrier dysfunction.
5. Stem Cell Mobilisation and Mucosal Regeneration
The eight-fold increase in circulating stem cell markers documented at 20 HBOT sessions includes cell populations relevant to gut mucosal regeneration. Intestinal stem cells in the crypts of the gut lining are responsible for continuous renewal of the epithelium; in IBD, this regenerative capacity is impaired by the chronic inflammatory environment. HBOT's mobilisation of circulating stem cells and its creation of a more oxygen-rich mucosal environment supports the restoration of this regenerative capacity.
6. The Gut-Brain Axis
The connection between gut health and brain function is bidirectional and increasingly well-documented. Gut dysbiosis and intestinal inflammation influence neurotransmitter production (the gut produces approximately 90% of the body's serotonin), the composition of metabolites reaching the brain via the bloodstream, and the activity of the vagus nerve connecting gut and brain.
HBOT's combined effects on gut inflammation and neuroinflammation (check out our blog on HBOT and Brain Health) make it particularly relevant for people experiencing the brain fog, mood disturbance, and cognitive difficulties that frequently accompany gut conditions. These are not separate problems with separate solutions: they share a common inflammatory and vascular biology that HBOT addresses simultaneously.
Beyond IBD: Broader Gut Health Considerations
Inflammatory bowel disease is where the HBOT evidence is most developed. But the mechanisms described above are relevant to a broader range of gut conditions:
Irritable Bowel Syndrome (IBS) - dysbiosis of the gut microbiota is associated with IBS. The gut microbiota may modulate IBS symptoms via the epithelial barrier, mucosal immunity, microbial metabolites, and gut-brain signalling. HBOT's ability to modulate microbiota composition, reduce mucosal inflammation, and support barrier integrity is mechanistically relevant to IBS. Though direct IBS-specific HBOT trials are at an earlier stage than IBD research.
Post-infectious gut dysfunction - gut microbiome disruption following acute infection (including COVID-19 and other viral illnesses) is increasingly recognised as a driver of persistent gastrointestinal symptoms. The overlapping biology between post-COVID gut dysfunction and gut dysbiosis more broadly makes HBOT's microbiota-modulating effects potentially relevant.
Gut symptoms associated with systemic conditions - fibromyalgia, chronic fatigue, autoimmune conditions, and other systemic inflammatory conditions frequently include gastrointestinal symptoms that reflect the shared inflammatory biology. HBOT's systemic anti-inflammatory effects may improve gut symptoms as part of broader condition management.
Gut health as part of a longevity approach - the gut microbiome is increasingly recognised as a determinant of biological ageing and long-term health. HBOT's ability to reduce systemic inflammation, support barrier integrity, and modulate microbiota composition may contribute to gut health optimisation as part of a broader anti-ageing or longevity strategy.
HBOT for Gut Health at OxyPlus Newcastle
At OxyPlus, Newcastle's specialist HBOT clinic, we work with clients managing inflammatory bowel conditions and other gut health challenges. Here is how we approach it:
Initial Consultation - We discuss your gut health history, current diagnosis, treatment, and what your gastroenterologist has advised. For IBD clients, we liaise with your clinical team where appropriate.
Personalised Protocol - For IBD, the evidence points toward courses of 40–60 sessions for sustained benefit. For other gut conditions, we discuss appropriate protocols based on your individual situation.
Adjunctive Framework - HBOT works alongside your existing treatment, not instead of it. We are transparent about where the evidence is strong and where it is still developing.
We are based in Newcastle and serve clients from across the North East - including Gateshead, Sunderland, Durham, Northumberland, and Teesside.
Frequently Asked Questions
-
A: A 2025 prospective study published in the Journal of Translational Medicine found HBOT significantly reduced CRP and Crohn's Disease Activity Index, while modulating gut microbiota composition. Published case series document patients achieving remission. HBOT is considered a promising adjunctive therapy alongside conventional Crohn's treatment.
-
A: The NIDDK is currently funding a 15-site multicentre trial specifically examining HBOT for hospitalised UC patients, reflecting serious institutional investment in this question. The mechanistic rationale is strong and case evidence is encouraging. Definitive large-scale RCT results are pending from the active trials.
-
A: A 2025 clinical study in Crohn's disease patients found that HBOT changed the composition of gut microbiota, reducing dysbiosis. The mechanism relates to HBOT's oxygenation of gut tissue creating a less favourable environment for harmful anaerobic bacteria while supporting the conditions for a more balanced microbial community.
-
A: Direct HBOT trials in IBS are at an earlier stage than for IBD. However, the mechanisms - reducing mucosal inflammation, supporting barrier integrity, modulating microbiota composition, and addressing the gut-brain axis — are all relevant to IBS pathophysiology. We discuss individual circumstances during consultation.
-
A: For IBD, the evidence points toward longer courses (40–60 sessions) for sustained benefit. The CRP reductions in the Crohn's study were achieved over a defined treatment course. At OxyPlus Newcastle, we design individual protocols during your initial consultation based on your condition and goals.
-
A: OxyPlus is Newcastle's specialist HBOT clinic, offering medical-grade hyperbaric oxygen therapy with thorough clinical consultations. We serve clients across Newcastle, Gateshead, Sunderland, Durham, Northumberland, and Teesside. Visit oxyplus.co.uk to book your initial consultation.
The Bottom Line
The gut's relationship with oxygen is more complex, and more important, than most people realise. In inflammatory gut conditions, tissue hypoxia drives a cycle of inflammation and impaired healing that sustains the disease. HBOT addresses this at its biological root, reversing mucosal hypoxia, modulating the microbiome, reducing inflammatory cytokines, and supporting the epithelial barrier integrity that underlies gut health.
The evidence is most developed for Crohn's disease and ulcerative colitis, where clinical trials have demonstrated measurable improvements in inflammatory markers, disease activity, and in some cases remission. Larger randomised controlled trials, including an active 15-site US multicentre trial, will further define where HBOT sits in the IBD treatment landscape.
For people in Newcastle and the North East managing gut conditions that have not responded adequately to conventional approaches, HBOT represents a biologically coherent, evidence-informed avenue worth an honest conversation.